side view of scientist looking into microscope in bright research lab

Life Sciences & Healthcare

Italy

CMS Adonnino Ascoli & Cavasola Scamoni has developed a broad expertise in the field of life sciences. The firm's life sciences practice includes the assistance of clients which operate in the fields of pharmaceuticals, biotechnology medical devices and more generally health care services. We regularly advise life science companies on corporate governance matters and licensing and contracts, as well as day-to-day corporate issues. The Team can count on professionals “borrowed” on a regular basis, to life sciences from other departments of the firm including team of corporate and intellectual property professionals who can boast a significant experience securing and defending patent positions and regulatory law issues in order for companies to comply with the Italian regulatory law.

Read more Read less

Choose area

    Pharmaceuticals

    Today the pharmaceutical industry is rapidly growing. This is a highly complex industry and represents one of the fastest growing on the market.

    Read more

    Feed

    Show only
    Laura Opilio
    01/02/2019
    Get­ting the Deal Through – Life Sci­ences 2019
    24/08/2018
    Gov­ern­ment Is­sues Brexit Tech­nic­al No­tice for Life Sci­ences
    On 23 Au­gust 2018, the UK Gov­ern­ment (the "Gov­ern­ment") is­sued the first wave of its tech­nic­al pa­pers de­signed to provide guid­ance to com­pan­ies to help pre­pare for a "No Deal" Brexit. In this scen­ario, there will be no "trans­ition peri­od" but rather the UK.
    06/06/2018
    European Com­mis­sion pro­poses SPC ex­emp­tions for gen­er­ics...
    18/05/2018
    EU Product Li­ab­il­ity Dir­ect­ive still an ad­equate tool, ac­cord­ing to...
    On 7 May 2018, the European Com­mis­sion pub­lished its fifth re­port on the per­form­ance of the EU Product Li­ab­il­ity Dir­ect­ive (Dir­ect­ive/85/374/EEC) in the mem­ber states. The dir­ect­ive in­tro­duced the concept of strict li­ab­il­ity for pro­du­cers of de­fect­ive products.
    01/02/2018
    Get­ting the Deal Through - Life Sci­ences 2018
    17/04/2018
    NGOs can ask the Com­mis­sion to re­view its de­cision on ge­net­ic­ally...
    The Gen­er­al Court de­cided in its de­cision of 14 March 2018 that non-gov­ern­ment­al or­gan­iz­a­tions (“NGOs”) can ask the Com­mis­sion to re­view its de­cision on au­thor­iz­ing the pla­cing on the mar­ket of ge­net­ic­ally mod­i­fied food and feed.
    11/01/2017
    Get­ting the Deal Through – Life Sci­ences 2017
    25/01/2018
    European Com­mis­sion as­sesses ad­equacy of Gen­er­al Food Law in food...
    In an eval­u­ation of the EU le­gis­lat­ive frame­work for the 2002 Gen­er­al Food Law Reg­u­la­tion (GFLR), the European Com­mis­sion has found that this frame­work ap­pears to ad­dress most cur­rent trends, such as growth, com­pet­it­ive­ness and in­creased glob­al­isa­tion, but.
    22/12/2015
    Get­ting the Deal Through – Life Sci­ences 2016
    28/11/2017
    REACH and Brexit – Some clar­ity gained but more cer­tainty re­quired
    Sev­en­teen months after the UK Ref­er­en­dum on wheth­er to re­main in or leave the EU a num­ber of areas re­main un­cer­tain for busi­ness.   For the chem­ic­als in­dustry[i] whose products form an in­teg­ral part of our daily lives, the status of the corner­stone of the chem­ic­als.
    15/12/2015
    CMS Glob­al Lifes­ci­ences For­um 2015
    Shap­ing the fu­ture through in­nov­a­tion and col­lab­or­a­tion
    06/11/2017
    Brexit: State of play for Life Sci­ences com­pan­ies
    With the UK pre­par­ing to leave the European Uni­on (EU) on 30 March 2019, life sci­ences com­pan­ies are plan­ning ahead for changes to the busi­ness and reg­u­lat­ory en­vir­on­ment. Dis­cus­sions at the EU Sum­mit on 19 Oc­to­ber 2017 primar­ily fo­cused on what are re­garded.